Decrease of blood anti-α1,3 Galactose Abs levels in multiple sclerosis (MS) and clinically isolated syndrome (CIS)...

Area of Science:

• Immunology
• Neuroscience
• Microbiome Research

Background:

• The exact cause of multiple sclerosis (MS) is unknown.
• Epstein-Barr virus (EBV) infection, causing Infectious Mononucleosis (IMN), is a potential factor in MS etiology.
• Increased antibodies like anti-Neu5Gc during IMN might compromise the blood-brain barrier, allowing viral entry and immune cell infiltration into the brain.

Purpose of the Study:

• To investigate the antibody titers of anti-Neu5Gc and anti-α1,3 Galactose in patients with IMN, MS, and Clinically Isolated Syndrome (CIS).
• To compare these antibody levels with those in healthy individuals and patients with other central nervous system pathologies.
• To explore the potential link between gut microbiota and antibody responses in MS and CIS.

Main Methods:

• Quantified antibody titers against Neu5Gc and α1,3 Galactose (anti-Gal) in serum samples.
• Analyzed data from 49 IMN patients, 76 MS patients, 73 CIS patients, and age/gender-matched healthy controls.
• Compared antibody levels between patient groups, healthy controls, and individuals with non-MS/CIS central nervous system conditions.

Main Results:

• Anti-Gal and anti-Neu5Gc antibodies were significantly elevated during IMN, but not with cytomegalovirus (CMV) infection.
• Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS) patients showed no change in anti-Neu5Gc levels.
• A significant decrease in anti-Gal antibodies was observed in MS/CIS patients compared to controls and those with other neurological diseases.

Conclusions:

• The findings suggest that elevated anti-Neu5Gc and anti-Gal antibodies during IMN may play a role in MS pathogenesis.
• The decrease in anti-Gal antibodies in MS/CIS patients indicates a potential alteration in gut microbiota or immune response to gut microbial epitopes.
• Further research into the gut microbiome's role in MS development is warranted.